CN105688230B - 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 - Google Patents
七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 Download PDFInfo
- Publication number
- CN105688230B CN105688230B CN201610074828.0A CN201610074828A CN105688230B CN 105688230 B CN105688230 B CN 105688230B CN 201610074828 A CN201610074828 A CN 201610074828A CN 105688230 B CN105688230 B CN 105688230B
- Authority
- CN
- China
- Prior art keywords
- folic acid
- preparation
- cyanine dyes
- polyethylene glycol
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011724 folic acid Substances 0.000 title claims abstract description 46
- 229960000304 folic acid Drugs 0.000 title claims abstract description 38
- 150000002475 indoles Chemical class 0.000 title claims abstract description 27
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 title claims abstract description 27
- 239000004698 Polyethylene Substances 0.000 title claims abstract description 20
- 229920000573 polyethylene Polymers 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000002131 composite material Substances 0.000 title claims abstract description 12
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 title abstract description 23
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 43
- 235000019152 folic acid Nutrition 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 9
- 229940064302 folacin Drugs 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- 239000000975 dye Substances 0.000 claims description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 10
- -1 methine indoles Chemical class 0.000 claims description 9
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 229940068917 polyethylene glycols Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 230000037452 priming Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 230000008685 targeting Effects 0.000 abstract description 7
- 201000005202 lung cancer Diseases 0.000 abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 abstract description 6
- 239000007850 fluorescent dye Substances 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 230000008520 organization Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical group CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical group C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical group O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 238000007626 photothermal therapy Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000513 vascular toxicity Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一种七甲川吲哚花菁染料‑聚乙二醇‑叶酸复合物及制备方法和应用,所述七甲川吲哚花菁染料‑聚乙二醇‑叶酸可以改进小分子近红外荧光染料普遍存在的脂溶性问题,同时增强对有关组织的靶向特异性。其方法反应条件温和,步骤简单,易于操作,原料成本低;用本方法制备的七甲川吲哚花菁染料‑聚乙二醇‑叶酸复合物,水溶性好,应用安全性提高,有利于减小对正常细胞的毒性;七甲川吲哚花菁染料‑聚乙二醇‑叶酸对具有高表达叶酸受体的肺癌的靶向性。
Description
技术领域
本发明属于生物技术领域,特别涉及一种七甲川吲哚花菁染料-聚乙二醇-叶酸的制备方法以及用于高表达叶酸受体的肺癌细胞的检测。
背景技术
荧光成像在医学和生物学研究中具有独特的优势,其中近红外区域(600nm-1000nm)由于生物分子的光吸收最低,自发荧光最弱,大量的红外光可以穿透组织和皮肤而被检测到。由于近红外区域灵敏度高,可以提供实时动态肿瘤活体成像,因此近年来,近红外活体成像技术引起了越来越多学者和外科医生的关注。
在近红外荧光成像技术中,荧光探针的质量至关重要。目前所研究的近红外小分子荧光染料中,普遍存在一个水溶性差、在生物体内代谢时间短的问题,应用时需要事先溶于二甲基亚砜(DMSO)等有机溶剂中。申请人在前期研究中合成了一系列七甲川吲哚花菁染料(史春梦等.一组碳花青染料的类的近红外荧光化合物的用途.CN101518528 A;史春梦等.七甲川吲哚花菁染料及其合成方法和应用.CN102268191 A),虽然这种染料具有良好的近红外荧光特性、一定的靶向肿瘤杀伤作用和光敏/热敏效果(Caixia Yue,Peng Liu,Mingbin Zheng,etc.IR-780 dye loaded tumor targeting theranostic nanoparticlesfor NIR imaging and photothermal therapy.Biomaterials,2013,34:6853-6861;XuTan,Shenglin Luo,Dechun Wang,etc.A NIR heptamethine dye with intrinsic cancertargeting,imaging and photosensitizing properties.Biomaterials,2012,33(7):2230-2239),然而由于该类花菁染料是脂溶性的,在应用时需要事先溶于DMSO中。而DMSO是一种氢键破坏剂,存在严重的毒性作用,与蛋白质疏水基团发生作用,导致蛋白质变性,具有血管毒性和肝肾毒性;同时对人体皮肤具有很好的渗透性,可以将一些溶于其中的有毒物质带入肌肤,所以在应用时存在潜在的安全性风险。
发明内容
本发明的目的是提供一种七甲川吲哚花菁染料-聚乙二醇-叶酸复合物和制备方法及应用,所述七甲川吲哚花菁染料-聚乙二醇-叶酸复合物改进了小分子近红外荧光染料普遍存在的脂溶性问题,同时增强对叶酸受体肺癌的靶向特异性。该方法反应条件温和,步骤简单,易于操作,原料成本低;用本方法改性所得的近红外荧光染料,水溶性好,应用安全性提高,有利于减小对正常细胞的毒性;七甲川吲哚花菁染料-聚乙二醇-叶酸对具有高表达叶酸受体的肺癌的靶向性将有所增强。
为实现上述目的,本发明的技术方案为:
七甲川吲哚花菁染料-聚乙二醇-叶酸复合物(IR-808-PEG-FA),该复合物的结构式为:
七甲川吲哚花菁染料-聚乙二醇-叶酸复合物(IR-808-PEG-FA)的制备方法,有以下步骤:
a.取七甲川吲哚花菁染料(IR-808)、双氨基聚乙二醇(PEG)、N,N'-二环己基碳酰亚胺(DCC)和N-羟基琥珀酰亚胺(NHS),加入二氯甲烷(CH2Cl2)、四氢呋喃(THF)和N,N二甲基甲酰胺(DMF)混合溶剂,惰性气氛,室温下避光搅拌反应,得到IR-808-PEG;
b.取叶酸(FA)、N,N'-二环己基碳酰亚胺和N-羟基琥珀酰亚胺,加入二氯甲烷、四氢呋喃和N,N-二甲基甲酰胺混合溶剂,惰性气氛,室温下避光搅拌反应,活化叶酸,得到叶酸活性酯(FA-NHS);
c.步骤a得到的IR-808-PEG溶液与步骤b中得到的叶酸活性酯FA-NHS混合,惰性气氛,室温下避光搅拌反应,得到IR-808-PEG-FA;
d.步骤c得到的IR-808-PEG-FA纯化。
所述七甲川吲哚花菁染料为其N-烷基侧链不同链长(n=1-12),且末端为羧基的七甲川吲哚花菁染料类似物。
步骤a所述N,N'-二环己基碳酰亚胺:N-羟基琥珀酰亚胺:七甲川吲哚花菁染料的摩尔比为3:3:0.5-3,所述七甲川吲哚花菁染料:双氨基聚乙二醇的摩尔比为1:2-4。
所述的聚乙二醇两端为氨基封端的直链聚合物且分子量为600-10000。
步骤b所述N,N'-二环己基碳酰亚胺:N-羟基琥珀酰亚胺:叶酸的摩尔比为在3:3:0.5-3。
步骤b所述活化反应时间为10-100h。
IR-808-PEG,和FA-NHS的摩尔比为1:2-4。
步骤a所述混合溶剂二氯甲烷:四氢呋喃:N,N-二甲基甲酰胺的体积比为3:1-1.5:1-1.5。
步骤b所述混合溶剂二氯甲烷:四氢呋喃:二甲基亚砜的体积比为3:1-1.5:1-1.5。
步骤a和步骤c所述的惰性气氛,其惰性为氮气或氩气。
步骤d所述的纯化在避光条件下进行,其方法是:所得IR-808-PEG-FA溶液高速离心,除去沉淀,旋蒸溶液后,柱层析,收集洗脱部分。
所述柱层析的洗脱剂为二氯甲烷和甲醇混合溶剂,其体积比为V二氯甲烷:V甲醇=20:0.1-2。
七甲川吲哚花菁染料-聚乙二醇-叶酸复合物在制备用于高表达叶酸受体的肿瘤细胞检测中的试剂盒的应用,如:肺癌等肿瘤细胞的检测等。
本发明对现有的七甲川吲哚花菁染料进行了改性,提高其水溶性。另外,该制备工艺条件温和,操作方便,原料经济,易于实施。
本发明的有益效果:
通过聚乙二醇(PEG)修饰解决了染料的水溶性问题,降低了染料潜在的毒副作用,提高了其临床应用的潜能;
通过叶酸(FA)修饰增强了荧光探针对是对高表达叶酸受体的肺癌、卵巢癌、乳腺癌等肿瘤细胞的主动靶向性,可作为肿瘤细胞检测的试剂盒。
附图说明
图1为IR808-聚乙二醇-叶酸(IR-808-PEG-FA)的结构表征核磁氢谱;
图2为IR808-聚乙二醇-叶酸(IR-808-PEG-FA)荧光光谱图;
图3为IR808-聚乙二醇-叶酸(IR-808-PEG-FA)的细胞毒性评价;
图4为IR808-聚乙二醇-叶酸(IR-808-PEG-FA)被叶酸受体高表达的肺癌细胞高效摄取。
具体实施方式
实施例中所采用的试剂与仪器:
溶剂二氯甲烷、THF、DMF、甲醇均需经过蒸馏纯化与分子筛干燥处理。其他所涉及的化学试剂为市售的分析纯产品;
所有反应均处于氩气及避光保护条件下进行,且硅胶薄层层析监测至反应结束。硅胶薄层层析使用烟台市芝罘黄务硅胶开发试验厂所生产的高效薄层层析硅胶板(型号CF-254),采用254nm荧光下直接检测或采用磷钼酸、茚三酮、溴甲酚绿、碘显色等官能团显色剂进行检测。
柱层析用于染料分子的最终纯化,采用烟台市芝罘黄务硅胶开发试验厂生产的层析硅胶(10-40μ)。层析用有机溶剂均为分析纯,且经过重蒸干燥处理。目标化合物1H NMR由美国Varian公司生产的Mercury Plus-400核磁共振谱仪测定,TMS作内标,CDCl3作溶剂。
所用A549和H460为两种肺癌肿瘤细胞,均从美国ATCC公司购买,且按照其要求相应培养基进行细胞培养。
所举实施例是为了更好的描述本发明的内容,并不是本发明的内容仅限于所举实例。该领域的相关人员根据上述发明内容对实施方案进行非实质的改进和调整,仍属于本发明的保护范围。
实施例1. IR808-PEG的制备(步骤a)
按照摩尔比1:1:1.3:1依次称取七甲川吲哚花菁染料IR-808(其结构见上述反应式),氨基封端PEG(分子量3400),N,N'-二环己基碳酰亚胺和N-羟基琥珀酰亚胺置于干燥锥形瓶中后,依次量取二氯甲烷,四氢呋喃,N,N-二甲基甲酰胺的体积为15mL,3mL,3mL作为反应的混合溶剂,充入氩气1-2min后,密封,避光,室温,持续搅拌12-48h;
实施例2. 叶酸活性酯(FA-NHS)的制备(步骤b)
按照摩尔比1:1.2:1.1依次称取叶酸(FA),N,N'-二环己基碳酰亚胺和N-羟基琥珀酰亚胺置于干燥锥形瓶中后,依次量取二氯甲烷,四氢呋喃,N,N-二甲基甲酰胺15mL,3mL,3mL作为反应的混合溶剂,密封避光,室温,持续搅拌12-24h;所得产物即为叶酸活性酯FA-NHS.
实施例3. IR-808-PEG-FA的制备(步骤c)
将实施例1中反应所得IR-808-PEG与叶酸活性酯(FA-NHS)充分混合,通入氩气1-2min,密封,避光,持续搅拌24-72h,高速离心除去沉淀,旋蒸除去有机溶剂后层析法进行纯化,洗脱剂组成比例V二氯甲烷:V甲醇=20:1-0:1,收集最后洗脱部分即为制备目标产物IR-808-PEG-FA。以氘代氯仿为溶剂核磁共振波谱测定产物结构,结果如图1所示;以PBS(pH=7.4)为溶剂检测产物的荧光性能,结果如图2所示。
实施例4. 细胞毒性评价
A549和H460细胞接种于96孔板,37℃,5%CO2孵育过夜,分别用2.6μM与5.2μM的IR-808-PEG-FA和IR-808处理48h后,CCK-8法检查各自肿瘤细胞活力,细胞活力(%)=(实验组OD值-空白组OD值)/(对照组OD值-空白组OD值)×100%。
结果如图3所示。
实施例5. A549和H460肺癌细胞对IR-808-PEG-FA的摄取检测
A549和H460细胞接种于6孔板,37℃,5%CO2孵育过夜,分别加入2.6μM与5.2μM的IR-808-PEG-FA和IR-808(其结构上述见反应式),20h后胰酶消化收集细胞,PBS漂洗两遍后重悬细胞,流式细胞仪分别检查10000个各自肿瘤细胞的平均荧光强度,633nm激发,780nm收集信号,结果如图4所示。
Claims (10)
1.一种七甲川吲哚花菁染料-聚乙二醇-叶酸复合物,其特征在于,该复合物的结构式为:
2.七甲川吲哚花菁染料-聚乙二醇-叶酸复合物(IR-808-PEG-FA)的制备方法,其特征在于,有以下步骤:
a.取七甲川吲哚花菁染料、双氨基聚乙二醇、N,N'-二环己基碳酰亚胺N-羟基琥珀酰亚胺,加入二氯甲烷、四氢呋喃和N,N二甲基甲酰胺混合溶剂,惰性气氛,室温下避光搅拌反应,得到IR-808-PEG;
b.取叶酸、N,N'-二环己基碳酰亚胺和N-羟基琥珀酰亚胺,加入二氯甲烷、四氢呋喃和N,N-二甲基甲酰胺混合溶剂,惰性气氛,室温下避光搅拌反应,活化叶酸,得到叶酸活性酯(FA-NHS);
c.步骤a得到的IR-808-PEG溶液与步骤b中得到的叶酸活性酯FA-NHS混合,惰性气氛,室温下避光搅拌反应,得到IR-808-PEG-FA;
d.步骤c得到的IR-808-PEG-FA纯化。
3.根据权利要求2所述的制备方法,其特征在于:所述七甲川吲哚花菁染料为其N-烷基侧链不同链长(n=1-12),且末端为羧基的七甲川吲哚花菁染料类似物。
4.根据权利要求2所述的制备方法,其特征在于:步骤a所述N,N'-二环己基碳酰亚胺:N-羟基琥珀酰亚胺:七甲川吲哚花菁染料的摩尔比为3:3:0.5-3,所述七甲川吲哚花菁染料:双氨基聚乙二醇的摩尔比为1:2-4;所述混合溶剂二氯甲烷:四氢呋喃:N,N-二甲基甲酰胺的体积比为3:1-1.5:1-1.5。
5.根据权利要求2所述的制备方法,其特征在于:所述双氨基聚乙二醇两端为氨基封端的直链聚合物且分子量为600-10000。
6.根据权利要求2所述的制备方法,其特征在于:步骤b所述N,N'-二环己基碳酰亚胺:N-羟基琥珀酰亚胺:叶酸的摩尔比为在3:3:0.5-3;混合溶剂二氯甲烷:四氢呋喃:二甲基亚砜的体积比为3:1-1.5:1-1.5。
7.根据权利要求2所述的制备方法,其特征在于:步骤b所述活化反应时间为10-100h。
8.根据权利要求2所述的制备方法,其特征在于:步骤c所述的IR-808-PEG:叶酸活性酯的摩尔比为1:2-4。
9.根据权利要求2所述的制备方法,其特征在于:步骤d所述的纯化在避光条件下进行,其方法是:所得IR-808-PEG-FA溶液高速离心,除去沉淀,旋蒸溶液后,柱层析,收集洗脱部分,柱层析的洗脱剂为二氯甲烷和甲醇混合溶剂,其体积比为V二氯甲烷:V甲醇=20:0.1-2。
10.七甲川吲哚花菁染料-聚乙二醇-叶酸复合物在制备用于高表达叶酸受体的肿瘤细胞检测中的试剂盒的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610074828.0A CN105688230B (zh) | 2016-02-02 | 2016-02-02 | 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610074828.0A CN105688230B (zh) | 2016-02-02 | 2016-02-02 | 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105688230A CN105688230A (zh) | 2016-06-22 |
CN105688230B true CN105688230B (zh) | 2018-12-11 |
Family
ID=56230180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610074828.0A Active CN105688230B (zh) | 2016-02-02 | 2016-02-02 | 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105688230B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110542671B (zh) * | 2018-05-29 | 2021-10-26 | 中国科学院过程工程研究所 | 一种有机双光子荧光探针、其制备及应用 |
CN110882386A (zh) * | 2019-09-18 | 2020-03-17 | 青岛大学 | 一种靶向水溶性近红外染料及其制备方法 |
CN115160817A (zh) * | 2022-07-01 | 2022-10-11 | 北京天罡助剂有限责任公司 | 一种近红外花菁染料及其制备方法 |
CN115266664B (zh) * | 2022-07-13 | 2023-05-09 | 广州沙艾生物科技有限公司 | 一种免疫细胞治疗制剂体外杀伤效力评价方法及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002743A1 (en) * | 1996-07-15 | 1998-01-22 | Sensors Technology Company B.V. | Sensors |
CN101440282A (zh) * | 2008-12-18 | 2009-05-27 | 中国药科大学 | 近红外荧光分子探针及其合成方法和用途 |
CN101946171A (zh) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | 荧光化合物 |
CN102438659A (zh) * | 2009-03-19 | 2012-05-02 | 通用电气公司 | 光学成像剂 |
CN102631681A (zh) * | 2012-01-07 | 2012-08-15 | 盐城工学院 | 一种长循环靶向、光敏抗肿瘤药物偶联物及其制备方法 |
CN102895670A (zh) * | 2012-11-09 | 2013-01-30 | 中国人民解放军第三军医大学野战外科研究所 | 水溶性分子靶向卟吩光敏剂及其制备方法 |
-
2016
- 2016-02-02 CN CN201610074828.0A patent/CN105688230B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002743A1 (en) * | 1996-07-15 | 1998-01-22 | Sensors Technology Company B.V. | Sensors |
CN101946171A (zh) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | 荧光化合物 |
CN101440282A (zh) * | 2008-12-18 | 2009-05-27 | 中国药科大学 | 近红外荧光分子探针及其合成方法和用途 |
CN102438659A (zh) * | 2009-03-19 | 2012-05-02 | 通用电气公司 | 光学成像剂 |
CN102631681A (zh) * | 2012-01-07 | 2012-08-15 | 盐城工学院 | 一种长循环靶向、光敏抗肿瘤药物偶联物及其制备方法 |
CN102895670A (zh) * | 2012-11-09 | 2013-01-30 | 中国人民解放军第三军医大学野战外科研究所 | 水溶性分子靶向卟吩光敏剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Dodecanol-poly(d,l-lactic acid)-b-poly (ethylene glycol)-folate (Dol-PLA-PEG-FA)nanoparticles: Evaluation of cell cytotoxicity and selecting capability in vitro;Sujun Wang et al;《Colloids and Surfaces B: Biointerfaces》;20120731;第102卷;第130-135页 * |
两种近红外荧光探针的合成及肿瘤靶向研究;邓大伟 等;《中国激光》;20101110;第37卷(第11期);摘要,图3,"2.1试剂及仪器"、"3.1.1叶酸- PEG-ICG-Der-01的制备"部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN105688230A (zh) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105688230B (zh) | 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用 | |
Song et al. | Viscosity activated NIR fluorescent probe for visualizing mitochondrial viscosity dynamic and fatty liver mice | |
Cao et al. | Fast clearing RGD‐based near‐infrared fluorescent probes for in vivo tumor diagnosis | |
CN106008525B (zh) | 一种小分子有机纳米肿瘤光热治疗试剂及其制备方法 | |
Sha et al. | A mitochondria/lysosome-targeting fluorescence probe based on azonia-cyanine dye and its application in nitroreductase detection | |
Feng et al. | A 1, 8-naphthalimide-derived turn-on fluorescent probe for imaging lysosomal nitric oxide in living cells | |
Li et al. | A visible and near-infrared dual-fluorescent probe for discrimination between Cys/Hcy and GSH and its application in bioimaging | |
Xu et al. | Construction of chitosan-based fluorescent probe for real-time monitoring of viscosity changes in living cells with low cytotoxicity and high photostability | |
CN105693703A (zh) | 一种用于细胞内溶酶体pH成像的新型比率型荧光探针 | |
JP7093524B2 (ja) | 蛍光標識多糖、およびその調製方法と用途 | |
Li et al. | A novel endoplasmic reticulum-targeted ratiometric fluorescent probe based on FRET for the detection of SO2 derivatives | |
Zhong et al. | Real-time screening of hepatotoxins in natural medicine by peroxynitrite responsive lanthanide-based NIR-II luminescent probes | |
CN104258391B (zh) | 一种多功能刺激敏感型聚合物-纳米金笼载体及其制备方法 | |
CN106117241A (zh) | 一种检测癌细胞内溶酶体pH的荧光探针 | |
Wei et al. | Engineering a lipid droplet targeting fluorescent probe with a large Stokes shift through ester substituent rotation for in vivo tumor imaging | |
Pan et al. | Dual pH and oxygen luminescent nanoprobes based on graft polymers for extracellular metabolism monitoring and intracellular imaging | |
Wang et al. | A novel Fe3+ fluorescent probe based on rhodamine derivatives and its application in biological imaging | |
Guo et al. | Facile synthesis of multifunctional red-emissive carbon dots for fluorescent quercetin and pH sensing | |
CN108191884A (zh) | 一种多荧光单元复合分子的合成方法及其应用 | |
Liu et al. | Colorimetric/spectral dual-mode analysis of sensitive fluorescent probe based on 2, 3, 3-trimethyl-3H-benzo [e] indole detection of acid pH | |
CN110885309B (zh) | 一种pH敏感型探针分子及其应用 | |
Pan et al. | Intracellular potassium ion fluorescent nanoprobes for functional analysis of hERG channel via bioimaging | |
CN105503831B (zh) | 一种具有极酸性pH响应的近红外荧光探针及其制备方法和应用 | |
Li et al. | Turn-on fluorescence probing of amyloid fibrils by the proto-berberine alkaloids and the study of their interactions | |
Zhong et al. | In vivo study of a novel, safe, rapid, and targeted red carbon dot probe for recognition of tumors with high expression of folate enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191127 Address after: Chongqing city Shapingba street 400038 gaotanyan No. 30 Patentee after: PLA Military Medical University Address before: Chongqing city Shapingba street 400038 gaotanyan No. 30 gaotan village 99 building 1-1 Patentee before: Shi Chunmeng |
|
TR01 | Transfer of patent right |